ORIC
ORIC
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
1
$263K
Insider Sales
24
$6.95M
Total Volume
$7.22M
25 transactions
Net Activity
$6.69M
Net selling
Sentiment Rating
Moderate DistributionCEO Conviction Index
Liquidating / Profit Taking
Key Drivers
- •Heavy distribution: sales represent 96% of total transaction value.
- •CEO selling activity detected. Often driven by option expiration or diversification plans.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Chacko Jacob
Pres, CEO
$3.37M total
Piscitelli Dominic
CFO
$3.08M total
Heyman Richard A.
Dir
$328K total
You Angie
Dir
$263K total
Multani Pratik S
Chief Medical Officer
$170K total
Quick Actions
ORIC has an insider buy conviction of 4%, compared to the Unknown sector buy average of 6%.
Over the last 90 days, corporate insiders at ORIC (ORIC) engaged in a total of 25 transactions reported via SEC Form 4 filings. Among these, 1 were open-market purchases and 24 were sales. The total volume of insider trading reached $7.22M.
The net insider activity for ORIC shows a net selling bias of $6.69M. This activity represents a 4% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Chacko Jacob (Pres, CEO), who traded 125.0K shares valued at $1.35M on Sep 22, 2025.
symbol__ Stock Quote Price and Forecast
ORIC Pharmaceuticals, Inc. (ORIC) Stock Price, News, Quote & History
ORIC Pharmaceuticals, Inc. (ORIC) stock price, news, quote and history
Oric Pharmaceuticals stock maintained at Buy by BTIG, $26 target
Oric Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $21.79, Implies 190% Upside
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Target Lowered at HC Wainwright
Related News & Analyst Reports
Read original insights and educational research covering ORIC and the Unknown sector.
Sequoia Capital and the Mechanics of Venture Lock-Up Extensions
Sequoia Capital pioneered the use of voluntary lock-up extensions to signal portfolio company confidence. This report analyzes the market-price impact of Sequoia extension announcements and whether they have historically justified the delay.
Unusual Insider Buying Patterns: Spotting the Anomalies
Beyond simple purchase screens, unusual insider buying patterns, accelerating purchase velocity, off-hours filings, purchases during active 10b5-1 plans, can reveal extraordinary conviction. This guide documents nine pattern types and their historical signal accuracy.
Why Biotech Insiders Purchase Prior to Phase 3 Results
Buying stock before Phase 3 results is the highest-risk insider trade in biotech. This report examines the legal boundaries, the statistical frequency of such purchases, and whether insiders who buy pre-Phase-3 have historically outperformed those who buy after.
How to Use Insider Buying Data to Minimize Portfolio Downside
Insider buying clusters have historically preceded significant price recoveries after drawdowns. This risk-management guide shows how to overlay Form 4 data with portfolio holdings to reduce downside exposure at sector and position level.
Why C-Suite Buying During Market Corrections is a Strong Buy Signal
C-suite executives buying their own stock during broad market corrections have historically generated some of the strongest insider-signal returns. This report analyzes the 2020 COVID crash, the 2022 rate-shock selloff, and three prior corrections using Form 4 data.
Tracking Insiders in the Energy Sector: Key Indicators to Watch
Energy insiders, especially at exploration and production companies, show highly seasonal and commodity-correlated trading patterns. This report identifies the Form 4 signals in energy stocks that have historically preceded oil-price-driven rallies and sector-specific recoveries.
FAQs About ORIC Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for ORIC.